Related Experiment Video
Updated: Jul 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Technical challenges facing therapeutic cancer vaccines
Stephen Ward1, John Copier, Angus Dalgleish
1Onyvax Ltd, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
Therapeutic cancer vaccines for renal, colorectal, and prostate cancers show promise. This review covers cellular vaccine development progress and challenges in large-scale production for clinical trials and commercialization.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Therapeutic cancer vaccines are advancing, with notable progress in vaccines targeting renal, colorectal, and prostate cancers.
- Cellular vaccines represent a promising avenue in cancer immunotherapy.
Purpose of the Study:
- To review the progress in the development of cellular cancer vaccines.
- To identify and discuss the technical challenges hindering the advancement of these vaccines to Phase III clinical trials and commercial supply.
Main Methods:
- Literature review of recent advancements in cellular cancer vaccine development.
- Analysis of challenges in large-scale vaccine design, production, and scale-up.
- Examination of quality and yield assessment methodologies.
- Review of evolving regulatory guidelines for cellular vaccine production.
Main Results:
- Significant progress has been made in developing cellular vaccines for specific cancers.
- Key challenges include large-scale production, process scale-up, and consistent quality/yield assessment.
- Evolving regulatory guidelines are crucial for navigating clinical trials and commercialization.
Conclusions:
- Cellular cancer vaccines hold significant therapeutic potential.
- Overcoming manufacturing and regulatory hurdles is essential for successful clinical translation and market access.
- Continued research and development are vital for realizing the full potential of cancer vaccines.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
07:33Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
Published on: September 28, 2022
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Microorganisms in Medicine and Therapeutics
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...